Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed its efforts to advance GelrinC, an off-the-shelf hydrogel implant designed to support the body’s natural regeneration of damaged knee cartilage. Delivered as a liquid and cured in place with UV light, GelrinC forms a temporary scaffold that gradually degrades over roughly six to nine months, creating an environment intended to support the development of new cartilage without requiring cell harvesting or laboratory expansion. The company cites encouraging Phase 2 data from 56 patients, including improvements in pain and function through four years of follow-up, and says imaging has shown regenerated tissue with characteristics more closely resembling native hyaline cartilage. GelrinC has received CE Mark approval in Europe, while an FDA-authorized pivotal study in the U.S. and Europe is underway, with two-year follow-up data intended to support a potential Premarket Approval application.
To view the full article, visit https://nnw.fm/1iyZW
About Regentis Biomaterials Ltd.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R) is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement.
NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https://nnw.fm/RGNT
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
[email protected]
NetworkNewsWire is powered by IBN
